Trisalus Life Sciences, Inc. ( (TLSI) ) has released its Q2 earnings. Here is a breakdown of the information Trisalus Life Sciences, Inc. presented to its investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that integrates innovative delivery technology with standard-of-care therapies to improve treatment outcomes for patients with solid tumors. The company recently reported its financial results for the second quarter of 2025, highlighting significant revenue growth and strategic advancements.
In the second quarter of 2025, TriSalus Life Sciences achieved $11.2 million in revenue, marking a 52% increase year-over-year and a 22% growth from the previous quarter. The company also launched TriNav FLX, an enhancement to its Pressure-Enabled Drug Delivery (PEDD) platform, which has been well-received in the market.
Key financial metrics include an 84% gross margin, a reduction in operating losses to $7.3 million, and a net loss attributable to common stockholders of $9.0 million. The company also reported a decrease in research and development expenses and an increase in sales and marketing costs, reflecting its focus on expanding its commercial reach.
Looking ahead, TriSalus Life Sciences remains optimistic about its growth trajectory, reaffirming its full-year revenue growth guidance of at least 50%. The company plans to continue investing in clinical data and expanding its PEDD technology applications, aiming to enhance patient outcomes and drive further market penetration.